Bone Kidney Interactions

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2015 Jul 10

PMID 26156535

Citations 11

Authors

Thomas L Nickolas

Sophie A Jamal

Affiliations

Soon will be listed here.

Abstract

The fact that bone disease and kidney disease co-exist is well known. Formally, this inter-relationship is called chronic kidney disease mineral bone disorder or CKD-MBD. Traditionally, it was thought that bone played a passive role in CKD-MBD - specifically that kidney disease caused disordered mineral metabolism which resulted in bone disease and ultimately fractures. More recently however our understanding of bone function in general and the role that bone plays in CKD-MBD in particular, has changed. This chapter will briefly review epidemiology of fractures in chronic kidney disease (CKD) and the roles that imaging and measuring markers of mineral metabolism can play in assessing fracture risk. We will then review more recent data consistent with the concept MBD occurs early in the course of CKD and, via the secretion of novel molecules and/or signalling pathways, the bone can influence other organ systems.

Citing Articles

Comparative Pharmacokinetic Study of 5 Active Ingredients after Oral Administration of Zuogui Pill in Osteoporotic Rats with Different Syndrome Types.

Qiu J, Zhu Y, Xing J, Wang L, Zhang J, Yin H Int J Anal Chem. 2023; 2023:1473878.

PMID: 36998619 PMC: 10045483. DOI: 10.1155/2023/1473878.

Trabecular bone score and phalangeal quantitative ultrasound are associated with muscle strength and fracture risk in hemodialysis patients.

Catalano A, Gaudio A, Bellone F, La Fauci M, Xourafa A, Gembillo G Front Endocrinol (Lausanne). 2022; 13:940040.

PMID: 36157439 PMC: 9489856. DOI: 10.3389/fendo.2022.940040.

Thyroid and bone turnover markers in type 2 diabetes: results from the METAL study.

Chen Y, Zhang W, Chen C, Wang Y, Wang N, Lu Y Endocr Connect. 2022; 11(3).

PMID: 35196256 PMC: 9010813. DOI: 10.1530/EC-21-0484.

Bone Fragility Fractures in CKD Patients.

Pimentel A, Urena-Torres P, Bover J, Fernandez-Martin J, Cohen-Solal M Calcif Tissue Int. 2020; 108(4):539-550.

PMID: 33219822 PMC: 8052229. DOI: 10.1007/s00223-020-00779-z.

Disorders of Calcium and Phosphorus Metabolism and the Proteomics/Metabolomics-Based Research.

Sun M, Wu X, Yu Y, Wang L, Xie D, Zhang Z Front Cell Dev Biol. 2020; 8:576110.

PMID: 33015068 PMC: 7511772. DOI: 10.3389/fcell.2020.576110.

References

Schwartz A, Schafer A, Grey A, Vittinghoff E, Palermo L, Lui L . Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res. 2013; 28(6):1348-54. DOI: 10.1002/jbmr.1865. View

Koos R, Brandenburg V, Mahnken A, Schneider R, Dohmen G, Autschbach R . Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis. 2013; 22(3):317-25. View

Kramer I, Loots G, Studer A, Keller H, Kneissel M . Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2009; 25(2):178-89. PMC: 3153379. DOI: 10.1359/jbmr.090730. View

Herberth J, Branscum A, Mawad H, Cantor T, Monier-Faugere M, Malluche H . Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study. Am J Kidney Dis. 2010; 55(5):897-906. PMC: 2882243. DOI: 10.1053/j.ajkd.2009.12.041. View

Mani A, Radhakrishnan J, Wang H, Mani A, Mani M, Nelson-Williams C . LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007; 315(5816):1278-82. PMC: 2945222. DOI: 10.1126/science.1136370. View

Bacchetta J, Boutroy S, Guebre-Egziabher F, Juillard L, Drai J, Pelletier S . The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant. 2009; 24(10):3120-5. DOI: 10.1093/ndt/gfp262. View

Okuno S, Ishimura E, Tsuboniwa N, Norimine K, Yamakawa K, Yamakawa T . Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients. Osteoporos Int. 2012; 24(2):605-12. DOI: 10.1007/s00198-012-2003-0. View

Gundberg C, Nieman S, Abrams S, Rosen H . Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab. 1998; 83(9):3258-66. DOI: 10.1210/jcem.83.9.5126. View

Nickolas T, McMahon D, Shane E . Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006; 17(11):3223-32. DOI: 10.1681/ASN.2005111194. View

10.

Rao M, Jain P, Ojo T, Surya G, Balakrishnan V . Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients. Int J Nephrol. 2012; 2012:490623. PMC: 3395143. DOI: 10.1155/2012/490623. View

11.

Evenepoel P, Meijers B, de Jonge H, Naesens M, Bammens B, Claes K . Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008; 3(6):1829-36. PMC: 2572285. DOI: 10.2215/CJN.01310308. View

12.

Ensrud K, Lui L, Taylor B, Ishani A, Shlipak M, Stone K . Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007; 167(2):133-9. DOI: 10.1001/archinte.167.2.133. View

13.

Naylor K, Leslie W, Hodsman A, Rush D, Garg A . FRAX predicts fracture risk in kidney transplant recipients. Transplantation. 2014; 97(9):940-5. DOI: 10.1097/01.TP.0000438200.84154.1a. View

14.

Bervoets A, Spasovski G, Behets G, Dams G, Polenakovic M, Zafirovska K . Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41(5):997-1007. DOI: 10.1016/s0272-6386(03)00197-5. View

15.

Lee N, Sowa H, Hinoi E, Ferron M, Ahn J, Confavreux C . Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130(3):456-69. PMC: 2013746. DOI: 10.1016/j.cell.2007.05.047. View

16.

Baia L, Humalda J, Vervloet M, Navis G, Bakker S, de Borst M . Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol. 2013; 8(11):1968-78. PMC: 3817902. DOI: 10.2215/CJN.01880213. View

17.

Moyses R, Jamal S, Graciolli F, Dos Reis L, Elias R . Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?. Int Urol Nephrol. 2015; 47(5):847-50. DOI: 10.1007/s11255-015-0971-7. View

18.

Booth S, Centi A, Smith S, Gundberg C . The role of osteocalcin in human glucose metabolism: marker or mediator?. Nat Rev Endocrinol. 2012; 9(1):43-55. PMC: 4441272. DOI: 10.1038/nrendo.2012.201. View

19.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

20.

Raggi P, Giachelli C, Bellasi A . Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med. 2006; 4(1):26-33. DOI: 10.1038/ncpcardio0725. View